Theriva Biologics (TOVX) announced that the company had become aware of unusual trading activity in its common stock on the NYSE American on October 24. “The company has made inquiries and does not believe corrective actions are appropriate. The company is further announcing that there has been no material development in its business and affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action. However, on October 13, 2025, the company announced the presentation of expanded data from its VIRAGE trial investigating VCN-01 at a mini oral session at the European Society for Medical Oncology Annual Congress,” the company stated.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics Presents Promising Phase 2b Trial Data
- Theriva Biologics Secures $4M Through Warrant Agreement
- Theriva Biologics announces warrant inducement transaction for $4M in proceeds
- Theriva Biologics Presents Promising VCN-12 Preclinical Data
- Theriva Biologics Unveils VCN-12 Preclinical Data